BiOM® Changes Name to BionX™ - Gilde Healthcare

BiOM® Changes Name to BionX™

28 september 2015

New Name Highlights Company’s Core Competency in the Prosthetic Device Market

BEDFORD, Mass — iWalk (also known as BiOM®), a leader in the field of bionic prosthetic devices, announced today that the company has relaunched itself as BionX™ Medical Technologies, Inc. to better reflect its commitment to delivering bionic solutions that address critical unmet needs in the market. The company will unveil its new name and logo during its presentation at the Ladenburg Thalmann Healthcare Conference in New York City on Tuesday, September 29th. The corporate relaunch also reflects a series of significant company milestones, including the addition of an industry-leading executive team, market-leading product enhancements, international commercial expansion and ongoing support from reimbursement authorities such as the U.S. Department of Veterans Affairs and Workers’ Compensation payers across the U.S.

 “Our company was founded to revolutionize the prosthetic device industry by providing products, based on our bionic platform, that enable patients to have more freedom in their lives. Over the last year, we have made significant progress towards achieving this goal, having fortified our corporate organization, disciplined our commercial execution and continually expanded our IP portfolio and product pipeline,” said Dr. Charles S. Carignan, President and CEO of BionX. “Our new name helps communicate our commitment to offering bionic solutions that restore normalized limb function and improve quality of life. We are continually inspired by our patients who strive to achieve their greatest potential.”

The BiOM® Ankle, the company’s flagship product, is the only lower-limb prosthesis with powered propulsion for enhanced mobility. Only the BiOM Ankle provides power that emulates lost muscle function, control that mimics normal ankle movement and stability that automatically adjusts to any surface.

BionX is in the process of executing several key growth drivers including expanded insurance reimbursement, international commercial expansion and new product introductions.

About BionX™:

BionX is a leader in the field of prosthetic devices with their flagship product the BiOM Ankle, the only lower-limb prosthesis with powered propulsion for enhanced mobility. Privately held and headquartered in Bedford, Mass., BionX was originally founded in 2007 as iWalk by Dr. Hugh Herr, Director and Principal Investigator of the Biomechatronics Group of MIT’s Media Laboratory, and funded by leading investment firms including WFD Ventures, General Catalyst Partners, Sigma Partners, and Gilde Healthcare Partners. The company has also received funding and support from the U.S. Department of Veterans Affairs and the U.S. Army’s Telemedicine and Advanced Technology Research Center (TATRC).

About the BiOM® Ankle:

The BiOM Ankle leverages patented technology to address the limitations of current lower-limb prostheses. Only the BiOM Ankle provides power that emulates lost muscle function, control that mimics normal ankle movement and stability that automatically adjusts to any surface. Clinical studies have shown that the BiOM Ankle can help people to walk faster and farther with less energy, improve balance and stability, reduce joint forces that lead to pain and more easily climb ramps, hills and stairs.1-7

WWW.BIONXMED.COM

WWW.TRY-BIOM.COM

Gilde Healthcare portfolio company Synexa Life Sciences acquires Finnish CRO Syrinx Bioanalytics to expand bioanalysis capabilities in clinical drug development

Gilde Healthcare portfolio company Synexa Life Sciences BV, a global leader in specialist biomarker and bioanalysis research services, has today announced that it has acquired Syrinx Bioanalytics, a bioanalytical CRO based in Turku, Finland. The move...
19 mei 2022

Gilde Healthcare company Amphista Therapeutics enters a up to $1.0 billion strategic collaboration with Merck

Amphista and Merck will collaborate to leverage Amphista’s proprietary EclipsysTM TPD platform and generate novel protein degrading therapeutics in oncology and immunology Collaboration includes up to €39 million ($44 million) in combined upfront and R&D funding...
4 mei 2022

Gilde Healthcare company Amphista Therapeutics enters a up to $1.25 billion strategic collaboration with Bristol Myers Squibb

Amphista and Bristol Myers Squibb to collaborate and leverage Amphista’s proprietary Eclipsys™ targeted protein degradation platform to develop novel protein degrading therapeutics Collaboration includes an upfront payment of $30 million, the potential for up to...
4 mei 2022